• Emergent BioSolutions Inc EBS.N reported quarterly adjusted earnings of 5 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -77 cents. The mean expectation of three analysts for the quarter was for a loss of 49 cents per share. Wall Street expected results to range from -64 cents to -35 cents per share.

• Revenue fell 29.6% to $194.70 million from a year ago; analysts expected $254.67 million.

• Emergent BioSolutions Inc's reported EPS for the quarter was a loss of 58 cents​.

• The company reported a quarterly loss of $31.3 million.

• Emergent BioSolutions Inc shares had fallen by 21.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 22.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "hold"

Wall Street's median 12-month price target for Emergent BioSolutions Inc is $13.50

This summary was machine generated from LSEG data March 4 at 12:53 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)